Please login to the form below

Not currently logged in
Email:
Password:

Intercept Pharma

This page shows the latest Intercept Pharma news and features for those working in and with pharma, biotech and healthcare.

Gilead NASH drug clears mid-stage trial, but rivals are looming

Gilead NASH drug clears mid-stage trial, but rivals are looming

Positive results to challenge Intercept in emerging disease area. Gilead has new data backing up its liver disease candidate GS-9674 in non-alcoholic steatohepatitis (NASH), tipped as one of the ... The new data shows Gilead’s drug is working as

Latest news

  • Intercept hit hard as FDA issues Ocaliva safety notice Intercept hit hard as FDA issues Ocaliva safety notice

    Intercept Pharma has only had a few months to revel in its first product launch before a safety warning from the FDA knocked it back. ... Intercept claimed an accelerated FDA approval for Ocaliva in May 2016 and followed that with an EMA green light in

  • Intercept gets EU nod for rare liver disease therapy Intercept gets EU nod for rare liver disease therapy

    Ocaliva approved as a combination treatment for primary biliary cholangitis. Intercept Pharma now has approval for its Ocaliva drug for primary biliary cholangitis (PBC) therapy Ocaliva on both sides of the ... Intercept launched Ocaliva in the US

  • Allergan buys two NASH drug developers in one day Allergan buys two NASH drug developers in one day

    pipeline. . The acquisition puts Allergan in a race to market with other FXR-targeting drugs for NASH, including Intercept Pharma which has a drug with mechanism already on the market for ... Allergan maintains AKN-083 is potentially best-in-class.

  • FDA panel backs Intercept's rare liver disease drug FDA panel backs Intercept's rare liver disease drug

    Intercept Pharma has secured a positive FDA advisory committee vote for its rare liver disease therapy Ocaliva, considered by some to be a blockbuster-in-waiting. ... Intercept owns worldwide rights to Ocaliva outside Japan and China, where it has

More from news
Approximately 3 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics